Table 1. Characteristics of Myocarditis and Pericarditis Reports After COVID-19 mRNA Vaccines.
| Characteristic | Patients, No. (%)a | ||||
|---|---|---|---|---|---|
| After first dose (n = 90) | After second dose (n = 207) | Total (N = 297) | |||
| Administered before June 1 | Administered on or after June 1 | Administered before June 1 | Administered on or After June 1 | ||
| Total reports, No. | 50 | 40 | 5 | 202 | 297 |
| Age, y | |||||
| Median (range) | 32 (12-81) | 23 (13-76) | 50 (34-61) | 23 (12-81) | 24 (12-81) |
| 12-17 | 5 (10.0) | 14 (35.0) | 0 (0.0) | 36 (17.8) | 55 (18.5) |
| 18-24 | 12 (24.0) | 7 (17.5) | 0 (0.0) | 77 (38.1) | 96 (32.3) |
| 25-39 | 11 (22.0) | 10 (25.0) | 2 (40.0) | 49 (24.3) | 72 (24.2) |
| ≥40 | 22 (44.0) | 9 (22.5) | 3 (60.0) | 40 (19.8) | 74 (24.9) |
| Sex | |||||
| Female | 18 (36.0) | 10 (25.0) | 3 (60.0) | 38 (18.8) | 69 (23.2) |
| Male | 32 (64.0) | 30 (75.0) | 2 (40.0) | 164 (81.2) | 228 (76.8) |
| Time to onset, median (IQR), db | 15 (7-29) | 4 (2-14) | 2 (2-73) | 2 (1-3) | 3 (2-8) |
| Vaccine product | |||||
| BNT162b2 | 39 (78.0) | 29 (72.5) | 4 (80.0) | 87 (43.1) | 159 (53.5) |
| mRNA-1273 | 11 (22.0) | 11 (27.5) | 1 (20.0) | 115 (56.9) | 138 (46.5) |
| Clinical diagnosis | |||||
| Myocarditis | 18 (36.0) | 13 (32.5) | 2 (40.0) | 72 (35.6) | 105 (35.4) |
| Pericarditis | 23 (46.0) | 15 (37.5) | 2 (40.0) | 45 (22.3) | 85 (28.6) |
| Myopericarditisc | 9 (18.0) | 12 (30.0) | 1 (20.0) | 85 (42.1) | 107 (36.0) |
| Healthcare use or outcome | |||||
| Emergency department visit | 49 (98.0) | 37 (92.5) | 5 (100.0) | 199 (98.5) | 290 (97.6) |
| In-patient hospitalization | 32 (64.0) | 24 (60.0) | 4 (80.0) | 150 (74.3) | 210 (70.7) |
| Intensive care unit admission | 1 (2.0) | 3 (7.5) | 0 | 10 (5.0) | 14 (4.7) |
| Death | 0 | 0 | 0 | 0 | 0 |
Abbreviations: BNT162b2, Pfizer-BioNTech Comirnaty; mRNA-1273, Moderna Spikevax.
a
Data are presented as the number (percentage) of patients unless otherwise indicated.
b
Two reports with unknown time to onset were excluded from this calculation.
c
Includes myocarditis or pericarditis (2 patients), myopericarditis (81 patients), and perimyocarditis (24 patients).